BLA 761468 · Gilead Sciences INC
Hepcludex
Bulevirtide-Gmod · Powder,For Solution
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, May 22, 2026: To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 22, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
4 Phase 3, 6 recruiting
FAERS reports
96
86 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS D and B Severe acute exacerbations of hepatitis D and hepatitis B may occur after HEPCLUDEX is discontinued, especially in patients with cirrhosis, who may be at increased risk of more severe flares or progression to hepatic decompensation. Monitor hepatic function closely with both clinical and laboratory follow-up, including hepatitis B virus (HBV) DNA and hepatitis delta virus (HDV) RNA viral load, for at least six months in patients who discontinue HEPCLUDEX. Resumption of antiviral therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS D and B See full prescribing information for complete boxed warning . Severe acute exacerbations of hepatitis D and hepatitis B may occur after HEPCLUDEX is discontinued, especially in patients with cirrhosis, who may...
What it is approved for
From the label in effect May 22, 2026.
HEPCLUDEX is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. This indication is approved under accelerated approval based on a decrease in HDV RNA and alanine aminotransferase (ALT) normalization [see Clinical Studies (14) ] . An improvement in disease-related clinical outcomes has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). HEPCLUDEX is a sodium taurocholate co-transporting polypeptide (NTCP)-directed HDV attachment inhibitor indicated for the treatment of chronic HDV infection in adults without cirrhosis or with compensated cirrhosis. This indication is approved under accelerated approval based on participants who achieved a decrease in HDV RNA and alanine aminotransferase (ALT) normalization. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 , 14 )
Mechanism: HEPCLUDEX is an antiviral drug [see Microbiology (12.4) ]. Mechanism of Action Bulevirtide is a synthetic 47-amino acid lipopeptide with a myristoylated N-terminus and an amidated C-terminus derived from amino acids 13-59 of the L-HBsAg preS1 domain from an HBV genotype (GT)-C consensus sequence (corresponding to GT-D preS1 amino acids 2-48). Bulevirtide inhibits HDV infection by binding to the HDV receptor NTCP on the plasma membrane of hepatocytes, blocking HDV attachment to NTCP.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 22, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterLabelReview
1 products under this application
- HEPCLUDEX · BULEVIRTIDE-GMOD 8.5MG · INJECTION, POWDER,FOR SOLUTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bulevirtide" as an intervention, any sponsor and status, largest first.
- Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT03852433 · 175 participants · Start May 31, 2019 · Primary completion Apr 5, 2022
Drug: Bulevirtide; Peginterferon Alfa-2a (PEG-IFN alfa) · For: Chronic Hepatitis Delta
Sites: Clichy, France; Grenoble, France; Lyon, France · 20 sites in all
- A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Pivotal-lookingRecruiting
Mirum Pharmaceuticals, Inc.Industry
NCT07200908 · 172 participants (planned) · Start Aug 27, 2025 · Primary completion Jun 30, 2027
Drug: Brelovitug 300 mg; Bulevirtide 2 mg and Brelovitug - 300 mg · For: Chronic Hepatitis D Infection
Sites: Graz, Austria; Sankt Pölten, Austria; Brno, Czechia · 57 sites in all
- Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT03852719 · 150 participants · Start Apr 17, 2019 · Primary completion Nov 26, 2020
Drug: Bulevirtide · For: Chronic Hepatitis Delta
Sites: New York, New York; Essen, Germany; Frankfurt am Main, Germany · 19 sites in all
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtidePivotal-lookingActive, not recruiting
Vir Biotechnology, Inc.Industry
NCT07128550 · 150 participants (planned) · Start Jul 30, 2025 · Primary completion Dec 2026
Drug: Tobevibart; Elebsiran and 1 more · For: Viral Hepatitis
Sites: Innsbruck, Austria; Vienna, Austria; Bobigny, France · 38 sites in all
- Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtidePivotal-lookingRecruiting
Mirum Pharmaceuticals, Inc.Industry
NCT07454837 · 120 participants (planned) · Start Feb 26, 2026 · Primary completion Aug 31, 2027
Drug: Brelovitug (BJT-778); Bulevirtide · For: Chronic Hepatitis D
Sites: Graz, Austria; Innsbruck, Austria; Lilienfeld, Austria · 46 sites in all
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPivotal-lookingActive, not recruiting
Vir Biotechnology, Inc.Industry
NCT07142811 · 100 participants (planned) · Start Aug 5, 2025 · Primary completion Mar 2029
Drug: Tobevibart; Elebsiran and 1 more · For: Viral Hepatitis
Sites: Brussels, Belgium; Edegem, Belgium; Sofia, Bulgaria · 27 sites in all
Hepatera Ltd.Industry
NCT02888106 · 90 participants · Start Apr 2016 · Primary completion Nov 22, 2019
Drug: Myrcludex B; PEG IFN alfa-2a and 1 more · For: Chronic Viral Hepatitis B With Delta-agent
Sites: Chelyabinsk, Russia; Krasnodar, Russia; Moscow, Russia · 7 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT05765344 · 74 participants · Start Mar 15, 2023 · Primary completion Jan 10, 2025
Drug: Bulevirtide; Bulevirtide · For: Hepatic Impairment; Healthy
Sites: Lake Forest, California; Miami, Florida; Orlando, Florida · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hepatic cirrhosis14
- pancytopenia10
- asthenia7
- drug ineffective7
- hepatitis d6
- virologic failure6
- fatigue5
- hepatic failure5
- hepatic fibrosis5
- thrombocytopenia5
- treatment noncompliance5
- drug-induced liver injury4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2021 | 11 |
| 2022 | 17 |
| 2023 | 12 |
| 2024 | 9 |
| 2025 | 9 |
| 2026 | 35 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H, Aleman S, Brunetto MR, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
Asselah T, Chulanov V, Lampertico P, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Multicenter Study
- Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L, Volmari A, Suri V, et al. · J Hepatol 2024 · Clinical Trial, Phase II, Randomized Controlled Trial
- Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
Wedemeyer H, Aleman S, Brunetto M, et al. · J Hepatol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Bulevirtide for chronic hepatitis D: phase III data.
Hindson J · Nat Rev Gastroenterol Hepatol 2023 · Clinical Trial, Phase III
- 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial.
Wedemeyer H, Aleman S, Blank A, et al. · J Hepatol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.